Tonix Q1 net loss $33M, cash $72M; Phase 3 TNX-102 SL topline due Q4 2023

Tonix Pharmaceuticals Holding Corp.

2023-Q1 EPS reported -$0.52

Net loss $33.0M ($0.52 per share) vs $26.4M ($1.61) in Q1 2022; cash $72.0M at Mar 31, 2023, down from $120.2M at Dec 31, 2022.
R&D expenses $26.5M (up from $18.4M) due to advancing clinical programs; G&A decreased to $7.4M from $8.0M.
Cash used in operations $32.9M vs $31.0M; share repurchase of 16.7M shares at $0.82 avg for $13.6M.
Pipeline: TNX-102 SL Phase 3 RESILIENT topline expected Q4 2023; TNX-601 ER Phase 2 enrolling; TNX-1900 Phase 2 enrolling.
Company reallocated resources to focus on late-stage CNS programs; delayed PTSD study in Kenya and reduced COVID-19 investment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 8, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001387131-23-006126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.